BioCryst Pharmaceuticals News

BioCryst Pharmaceuticals, Inc. today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's clinical programs at the following investor conferences: Links to live audio webcasts and replays of both presentations may be accessed on the BioCryst website at www.BioCryst.com .

BOSTON -- Noteworthy hedge fund trading in biotech and drug stocks, culled from the 13F filings for the first quarter: [Hedge funds and mutual funds that manage more than $100 million are required to disclose their equity holdings, options and convertible debt on a Form 13F filed SEC within 45 days of the end of a quarter.

The net loss for the quarter was $6.1 million, or 13 cents per share, compared to $13 million, or 29 cents per share during the same period a year ago.

Next week is a busy earnings season, with many quarterly earnings releases scheduled and a bunch of stocks to watch.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia RESEARCH TRIANGLE PARK, N.C.-- --BioCryst Pharmaceuticals, Inc.